Equities

Median Technologies SA

Median Technologies SA

Actions
TechnologyTechnology
  • Price (EUR)4.51
  • Today's Change0.505 / 12.63%
  • Shares traded513.52k
  • 1 Year change-2.28%
  • Beta1.2507
Data delayed at least 15 minutes, as of Sep 20 2024 16:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.

  • Revenue in EUR (TTM)22.23m
  • Net income in EUR-22.98m
  • Incorporated2002
  • Employees242.00
  • Location
    Median Technologies SALes Deux Arcs - Batiment B 1800Route des CretesVALBONNE 06560FranceFRA
  • Phone+33 493333777
  • Fax+33 492906599
  • Websitehttps://mediantechnologies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Diagnostic Medical Systems SA42.15m-9.76m17.08m147.00--1.34--0.4053-0.4982-0.24812.230.70230.80271.816.81286,755.10-18.73-12.33-33.53-22.1437.5837.72-23.33-16.450.7105-3.520.5938--19.5111.62-106.30------
Theraclion SA1.82m-3.68m17.61m29.00--3.11--9.66-0.0811-0.08110.03970.12360.11180.10810.680762,835.52-22.54-32.98-30.99-48.0181.8860.85-201.68-249.162.86-40.630.2564--47.49-1.1325.97---7.23--
Ikonisys SA448.56k-2.27m18.17m10.00--1.04--40.52-0.233-0.2330.04611.620.02111.1832.2144,856.00-10.65---12.50---20.88---505.54--0.0619-29.680.1244---27.28--7.38------
Mauna Kea Technologies SA10.48m-3.73m21.99m68.00------2.10-0.0578-0.05780.2126-0.28090.49052.312.45154,117.60-17.45-51.23-223.84-93.3033.6211.15-35.57-142.410.42874.292.38--40.139.1666.66---21.16--
Global Bioenergies SA486.33k-7.36m26.30m46.00------54.08-0.4036-0.40360.0267-0.00810.02762.740.118810,572.39-41.78-43.66-99.83-82.47-600.24-948.35-1,513.81-1,331.360.8447------365.8336.2527.78---19.49--
Biosynex SA92.98m-37.12m43.54m575.00--0.3553--0.4683-3.64-3.649.1011.920.37041.167.34161,700.90-14.1814.90-17.5119.4152.8451.92-38.3014.611.03-28.000.3459---52.7024.40-337.76------
AbL Diagnostics SA5.61m54.36k45.12m19.00830.866.6762.978.040.00340.00340.34830.420.3703--1.42295,411.600.35873.240.58844.43----0.96858.811.87-47.510.3389---35.8474.86-95.08-49.30----
Affluent Medical SAS0.00-15.65m71.79m59.00--1.79-----0.5409-0.54090.001.020.00----0.00-26.83---31.42-------------24.430.328-------2.80------
Carmat SA5.53m-53.35m74.59m162.00------13.49-1.76-1.760.1787-0.64190.09321.611.2830,379.12-89.92-76.92-113.71-94.38-535.50---964.91-4,636.641.69-17.371.63--710.72---0.3502--16.99--
Median Technologies SA22.23m-22.98m83.00m242.00------3.73-1.26-1.261.21-0.56080.6289-19.613.5591,842.98-65.02-54.57-186.81-157.51104.50101.57-103.40-93.701.40--2.21---6.1028.52-13.70--38.38--
Amplitude Surgical SA104.05m43.23m158.47m416.003.671.672.891.520.90020.90022.171.970.39550.56528.83244,244.1016.21-0.365819.44-0.426779.4178.3040.98-1.081.210.41630.5395--14.44-0.0271993.58--7.11--
Lumibird SA203.56m7.13m216.13m1.05k27.031.128.831.060.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
Data as of Sep 20 2024. Currency figures normalised to Median Technologies SA's reporting currency: Euro EUR

Institutional shareholders

13.84%Per cent of shares held by top holders
HolderShares% Held
Herald Investment Management Ltd.as of 31 Dec 2023522.35k2.84%
Aguja Capital GmbHas of 30 Jun 2023512.69k2.79%
Apo Asset Management GmbHas of 30 Apr 2024477.24k2.59%
Financi�re Arbevel SAas of 30 Dec 2022401.15k2.18%
Discover Capital GmbHas of 30 Jun 2024175.00k0.95%
Montpensier Finance SASas of 29 Dec 2023128.23k0.70%
Mandarine Gestion SAas of 29 Feb 2024115.00k0.63%
Groupama Asset Management SAas of 31 May 202480.58k0.44%
Pure Capital SAas of 31 Dec 202368.29k0.37%
Generali Asset Management SGR SpAas of 28 Feb 202265.00k0.35%
More ▼
Data from 30 Jun 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.